Seek Returns

BIIB vs. VTRS: Biogen vs. Viatris Stock Comparison

How do Biogen (BIIB) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Biogen (BIIB) and Viatris (VTRS)
Profile ItemBIIBVTRS
NameBiogen Inc.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization36.71 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateSeptember 17, 1991March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIIB
VTRS
GSPC
Loading price history…
Biogen (BIIB) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Biogen (BIIB) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Biogen (BIIB) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Total Return (1Y)65.44%108.98%
Total Return (3Y, Annualized)4.62%36.75%
Total Return (5Y, Annualized)-0.96%11.59%

Risk Profile

Drawdown History

BIIB
VTRS
GSPC
Loading price history…
Biogen (BIIB) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Biogen (BIIB) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Volatility (1Y, Annualized)34.58%32.53%
Beta (5Y)0.080.86
Max Drawdown (5Y)-64.35%-45.69%
Avg. Volume (3M)1.05M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIIB and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Sharpe Ratio (1Y)1.773.22
Sortino Ratio (1Y)2.775.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Biogen (BIIB) reports 1.87%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max
109.18%
Q3
6.23%
BIIB
1.87%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Biogen (BIIB) reports 3.38%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max
18.05%
Q3
4.78%
BIIB
3.38%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Biogen (BIIB) at 24.12% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max
83.12%
BIIB
24.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
ROE (TTM)1.87%-4.21%
ROA (TTM)4.94%2.91%
Net Margin (TTM)3.38%-4.13%
Operating Margin (TTM)24.12%13.85%
Gross Margin (TTM)75.77%41.13%

Growth

Revenue Growth

Biogen (BIIB) at 2.22% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Biogen (BIIB) reports EPS growth of -21.38%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Revenue Growth (YoY)2.22%-2.98%
Revenue Growth (3Y CAGR)-0.94%-4.20%
EPS Growth (YoY)-21.38%--
EPS Growth (3Y CAGR)-25.04%--

Financial Strength

Current Ratio (MRQ)

Both Biogen (BIIB) at 1.95 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BIIB
1.95
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max
1.42
Q3
0.65
BIIB
0.41
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Current Ratio (MRQ)1.951.55
Debt / Equity (MRQ)0.410.99
Net Debt / EBITDA1.972.64

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Biogen (BIIB) pays no dividend (payout 0.00%).

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Biogen (BIIB) trades at 107.51 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB
107.51
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; BIIB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max
58.18
Q3
25.77
Median
7.30
BIIB
3.57
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Biogen (BIIB) at 1.94 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max
13.53
Q3
6.54
Median
3.25
BIIB
1.94
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Biogen (BIIB) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Viatris (VTRS)
MetricBIIBVTRS
P/E Ratio (TTM)107.51--
P/S Ratio (TTM)3.571.55
P/B Ratio (MRQ)1.941.67
Free Cash Flow Yield (TTM)2.20%13.84%